View Exam | PowerPak

1. Which of the following emerging therapeutic options for treatment-resistant hypertension is characterized by a safety profile that includes the potential for urinary tract infections and genital infections?

A. SGLT-2 inhibitors B. Sacubitril/valsartan C. Firibastat D. Aprocitentan

2. Assume a patient is confirmed to have resistant hypertension after lifestyle modification and optimization of a 3-drug regimen with a RAS blocker, CCB, and hydrochlorothiazide as the diuretic. What would be the most appropriate next step in the management of this patient's blood pressure?

A. Add a mineralocorticoid receptor antagonist (eg, spironolactone) B. Replace hydrochlorothiazide with a thiazide-like diuretic (eg, chlorthalidone) C. Add hydralazine to the treatment regimen D. Recommend renal nerve ablation

3. Which of the following best describes the mechanism of action of aprocitentan?

A. Aminopeptidase A inhibitor B. Sodium-glucose cotransporter-2 inhibitor C. Dual endothelin receptor antagonist D. Angiotensin receptor neprilysin/inhibitor

4. In a clinical trial evaluating the efficacy and safety of once-daily aprocitentan in patients with grade 1-2 essential hypertension, analysis of the primary endpoint revealed

A. Significant reductions in unattended automated office BP from baseline to week 8 with 10 mg, 25 mg, and 50 mg doses B. Significant reductions in systolic and diastolic nighttime ambulatory BP from baseline to week 8 with 5 mg and 10 mg C. Significant reductions in 24-hour mean ambulatory systolic BP from baseline to week 8 with all doses studied D. Significant reductions in 24-hour mean ambulatory diastolic BP from baseline to week 8 with 25 mg and 50 mg doses

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following emerging therapeutic options for treatment-resistant hypertension is characterized by a safety profile that includes the potential for urinary tract infections and genital infections?

2. Assume a patient is confirmed to have resistant hypertension after lifestyle modification and optimization of a 3-drug regimen with a RAS blocker, CCB, and hydrochlorothiazide as the diuretic. What would be the most appropriate next step in the management of this patient's blood pressure?

3. Which of the following best describes the mechanism of action of aprocitentan?

4. In a clinical trial evaluating the efficacy and safety of once-daily aprocitentan in patients with grade 1-2 essential hypertension, analysis of the primary endpoint revealed

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following emerging therapeutic options for treatment-resistant hypertension is characterized by a safety profile that includes the potential for urinary tract infections and genital infections?

2. Assume a patient is confirmed to have resistant hypertension after lifestyle modification and optimization of a 3-drug regimen with a RAS blocker, CCB, and hydrochlorothiazide as the diuretic. What would be the most appropriate next step in the management of this patient's blood pressure?

3. Which of the following best describes the mechanism of action of aprocitentan?

4. In a clinical trial evaluating the efficacy and safety of once-daily aprocitentan in patients with grade 1-2 essential hypertension, analysis of the primary endpoint revealed

« Return to Activity

Customers who Purchased
this Activity also Purchased